

## Phospho-Bcr (Y177) Polyclonal Antibody

### Description

<b>Product type</b>	Primary Antibody
<b>Code</b>	BT-PHS00036
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Size</b>	20ul, 50ul, 100ul
<b>Immunogen</b>	The antiserum was produced against synthesized peptide derived from human Bcr around the phosphorylation site of Tyr177. AA range:144-193
<b>Mol wt</b>	142819
<b>Species reactivity</b>	Human, mouse
<b>Clonality</b>	Polyclonal
<b>Recommended application</b>	WB, ELISA
<b>Concentration</b>	1 mg/ml
<b>Full name</b>	Phospho-Bcr (Y177) Antibody
<b>Synonyms</b>	BCR; BCR1; D22S11; Breakpoint cluster region protein; Renal carcinoma antigen NY-REN-26

**This product is for research use only, not for use in human, therapeutic or diagnostic procedure.**

### Background

A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. BCR, RhoGEF and GTPase activating protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for BCR.

### Recommended Dilution

WB: 1: 500 - 1: 2000

ELISA: 1: 10000

Not yet tested in other applications.

### Images

No images.

### Storage

-20°C for one year